Title21 Health Solutions

"If you had a magic wand for a day, what would a digital solution look like?" ? Great question. ? Natalie Respond’s wish list was clear: ? 1. Scannable inventory 2. List of ‘favorites’ prepopulated in the software 3. Expiration alerts ? Turns out, a magic wand isn’t needed for this! ? Let us know what’s on your wish list. ? Watch the whole conversation here ‘Overcoming Inventory Challenges in Cell and Gene Therapy Labs – https://lnkd.in/gwXNmHEN #CGT #CellandGeneTherapy #BioTherapies

Product recalls and positive sterilities can cause a lot of stress in the lab, as Natalie Respond describes. ? Digital inventory management not only alleviates this but speeds up your ability to look back at your inventory and find the root causes. ? “…if some things were automated, that would sort of eliminate clerical errors and just kind of put barriers in place so that you don't have to stress as much.” To learn more, watch the complete webinar: https://lnkd.in/gwXNmHEN

Cell and gene therapies are transforming healthcare, offering hope for untreatable diseases. Yet, behind the scenes, reliance on manual processes creates hurdles—inefficiency, burnout, and delays that impact patients and lab professionals. The challenges are real, from complex workflows to personalized production bottlenecks. But there’s hope: automation is paving the way forward. Imagine: ? Streamlined workflows ? Real-time tracking ? Improved worker well-being ? Faster, safer, more affordable treatments By embracing automation, we can revolutionize the industry and empower those behind these life-saving therapies. ?? Read the full post to explore the challenges and solutions: https://lnkd.in/ghWXyqDZ #CGT #CellAndGeneTherapy #HealthcareInnovation #Automation #BioTherapies

Heather Purvis hosted last month’s webinar in conversation with Natalie Respond, Technical Manager, Stem Cell Laboratory at the Hospital of the University of Pennsylvania. The overarching theme was ‘Overcoming Inventory Challenges in Cell & Gene Therapy Labs’… ? "…but why is inventory management such a critical aspect of successful CGT operations?" ? Natalie lends her experience to uncover the ups and downs of supply operations and how her team works to deliver the best quality and patient outcomes possible. ? Natalie also gives her take on the role do digital systems have to play in this operational efficiency strategy. ? Watch the full webinar here: https://lnkd.in/gwXNmHEN

At Title21, we’ve pioneered CGT software solutions for over a decade, supporting advanced therapies—from oncology standards like bone marrow transplants to cutting-edge CAR-T and cell therapies. We enable seamless workflows, tracking and optimizing every step, from starter material collection to patient transfusion. As the industry evolves with consolidations, new players, and innovative therapies, our mission is clear: stay agile and flexible, empowering biotech companies to adapt quickly and deliver life-changing treatments. To learn more about us, visit https://lnkd.in/gKGRsGcC #CellTherapy #CGT #AdvancedTherapies #BioTherapies #PatientCare

Last week, we hosted an insightful webinar with Heather Purvis and Natalie Respond to dive into the inventory challenges and innovations shaping the future of cell and gene therapy labs. Here’s what we covered: ? Real-world experiences with inventory tracking and documentation. ? Strategies for optimizing workflows and communication. ? The future of digital solutions in CGT inventory management. Cell and gene therapy labs are at the forefront of life-saving innovations, but they face significant challenges—from supply chain disruptions to regulatory demands. This webinar is a must-watch for anyone looking to streamline operations, improve efficiency, and focus on what truly matters: delivering groundbreaking therapies to patients. ?? https://lnkd.in/gwXNmHEN #CellandGeneTherapy #CGT #InventoryManagement #Labtech #Scientist #Biotech #Lifescience #BioTherapies

This #WorldCancerDay, we stand in solidarity with patients, caregivers, and the incredible front-line workers in the life sciences who are tirelessly developing life-changing therapies. At Title21 Health Solutions, we celebrate the dedication of researchers, scientists, and healthcare professionals who drive innovation and hope in the fight against cancer. Your work is transforming lives and bringing us closer to a world where cancer is no longer a threat. Let’s continue to support advancements in treatment, early detection, and patient care. Together, we can make a difference. #WorldCancerDay #CancerResearch #LifeSciences #Innovation #BioTherapies #HealthcareHeroes #HopeForACure

As another week begins before embarking on the next amazing conference with powerhouse colleagues in anticipation of #Tandem2025 for #ASTCT, I am left reflecting on time spent?joining industry leaders at Phacilitate's Advanced Therapies Week in Dallas, where critical conversations shaped the future of cell and gene therapy. These discussions reinforced that while we've made remarkable progress, there are still key areas where we can collectively drive the field forward.? Here are some things that stood out for me: ? 1. #Education and engagement A crucial factor in unlocking patient access is the education and engagement of patients themselves and physicians. Without this we can neither develop and launch new therapies nor treat patients. We also need to engage payers to ensure these therapies are reimbursed and the investment cycle continues. This is solvable and it’s the responsibility of our field to ensure the next round of approvals are a commercial success ? 2. #Decentralized manufacturing is still hot There continues to be a lot of time and effort allocated to making decentralized manufacturing a reality. It was discussed heavily in the opening plenary with Boro Dropuli? focusing on reducing the cost per unit of CAR-T. The intersection of decentralized manufacturing and tech innovation holds the key to reducing these costs. 3. We need to reset the endpoints bar It was inspiring to hear from patients and their caregivers throughout the week. It brought to light the need to lower expectations in terms of endpoints. #Zolgensma set this bar very high with a cure, but other endpoints are just as important; from slowing disease progression to stopping progression to full cure. Different conditions will have varying degrees of what success looks like and we should be open to that as an industry. The headline? Engage patient advocacy groups EARLY. ? 4. It’s never too early to implement end-stage plans! Donna Rill at Triumvira Immunologics, Inc. shared her philosophy of beginning with the end in mind. Mapping out your expectations for commercialization early can save time and regulatory delays: -??????????????Understand BLA expectations -??????????????What does market access look like? -??????????????Comprehensive strategic planning early Donna’s big take home was that a lot of this is solved and supported by building in robust quality systems out of the gate, as your product will only be as good as the quality that supports it! It’s essential to make sure your document package is complete, comprehensive and up to date, going back 4-5 years to complete your documentation is not a good approach! ? As we reflect on these insights, it's clear that success in cell and gene therapy requires a holistic approach - from early #patientengagement to robust #qualitysystems, from innovative #manufacturingsolutions to realistic endpoint expectations.?

Cell and gene therapy (CGT) is transforming healthcare, offering hope for curing previously untreatable diseases. But behind these groundbreaking therapies lies a complex challenge: inventory management. From short shelf lives to specialized storage requirements and strict traceability, CGT labs face unique hurdles that demand precision and innovation. Front-line workers—technicians, scientists, and researchers—are at the heart of this battle, working tirelessly to deliver life-saving treatments. In this article, we explore: ? The unique inventory demands of CGT labs ? The pain points faced by front-line workers ? Practical strategies to overcome these challenges, from technology adoption to process optimization and enhanced collaboration Empowering front-line workers with the right tools and knowledge is key to advancing this revolutionary field and improving patient outcomes. ?? Read the full article here: https://lnkd.in/gCXXqVrN #CGT #CellandGeneTherapy #BioTherapies #InventoryManagement #PatientCare

At Advanced Therapies Week in Dallas, Title21's Director of Clinical Operations, Heather Purvis, joined an IBTV panel discussion titled "What We Don’t Know… Keeping Safety a Priority in Unchartered Territory". The panel explored the balance between rapid innovation and patient safety in cell and gene therapies (CGTs). Key takeaways included: - Urgent need for safe therapies: Rapid development must prioritize safety. - Empowered clinicians: Provide clinicians with the tools and freedom to focus on patient care. - Balanced approach: Speed is key, but must be balanced with careful review of data. - Adaptive regulation: Regulatory bodies need to keep pace with evolving therapies. - Patient trust: Prioritize safety at every step to maintain patient trust. Title21 Health Solutions supports these efforts by providing innovative software solutions that streamline workflows, enhance data management, and promote compliance, ultimately contributing to safer and more efficient CGT development. #ATW2025 #CellGeneTherapy #CGT #PatientSafety #Innovation #BioTherapies